Imperative Care
Commercial-stage medical technology company focused on endovascular treatments for thromboembolic diseases. Develops and commercializes integrated thrombectomy systems, investigational neurovascular implants, an endovascular robotics platform, and a digital health post-acute care offering. Operates clinical trials and regulatory programs to generate evidence and expand device indications, and supports product commercialization from development through clinical adoption.
Industries
Nr. of Employees
large (251-1000)
Imperative Care
Patents
Products
Integrated stroke thrombectomy system (access-through-reperfusion)
System-based aspiration thrombectomy platform that includes intracranial access platforms, vessel-matched aspiration catheters, an aspiration pump and sterile-field capture units for ischemic stroke treatment.
Large-bore continuous-vacuum thrombectomy system for venous applications
Large-bore aspiration system engineered for venous thromboembolism and pulmonary embolism that combines deep vacuum control with telescoping catheters and mechanical assist tools to remove clot effectively.
Investigational low-profile neurovascular stent system
Extremely low-profile nitinol stent scaffold with a proprietary anti-thrombogenic coating being evaluated to enable single antiplatelet therapy after aneurysm treatment.
Endovascular robotics platform (development-stage)
Robotic and automation platform under development to improve procedural precision, consistency and access for thrombectomy procedures.
Digital remote recovery platform for stroke survivors (Kandu Health)
Software platform delivering remote clinical support tailored to stroke survivors during the first 90 days of recovery.
Integrated stroke thrombectomy system (access-through-reperfusion)
System-based aspiration thrombectomy platform that includes intracranial access platforms, vessel-matched aspiration catheters, an aspiration pump and sterile-field capture units for ischemic stroke treatment.
Large-bore continuous-vacuum thrombectomy system for venous applications
Large-bore aspiration system engineered for venous thromboembolism and pulmonary embolism that combines deep vacuum control with telescoping catheters and mechanical assist tools to remove clot effectively.
Investigational low-profile neurovascular stent system
Extremely low-profile nitinol stent scaffold with a proprietary anti-thrombogenic coating being evaluated to enable single antiplatelet therapy after aneurysm treatment.
Endovascular robotics platform (development-stage)
Robotic and automation platform under development to improve procedural precision, consistency and access for thrombectomy procedures.
Digital remote recovery platform for stroke survivors (Kandu Health)
Software platform delivering remote clinical support tailored to stroke survivors during the first 90 days of recovery.
Services
Design and conduct of multicenter IDE and pivotal studies, investigator coordination, site enrollment and outcomes adjudication.
Remote clinical support platform tailored to stroke survivors for the first 90 days post-stroke delivered by licensed providers.
Design and conduct of multicenter IDE and pivotal studies, investigator coordination, site enrollment and outcomes adjudication.
Remote clinical support platform tailored to stroke survivors for the first 90 days post-stroke delivered by licensed providers.
Expertise Areas
- Endovascular thrombectomy (stroke and vascular)
- Clinical trial management and IDE/pivotal studies
- Medical device R&D for access and aspiration systems
- Neurovascular implant development (stent technologies)
Key Technologies
- Large-bore intracranial access catheters (.088" access)
- Aspiration thrombectomy catheters with asymmetric/beveled tips
- Continuous-vacuum aspiration pumps and sterile-field capture systems
- Mechanical assist tools for clot ingestion
News & Updates
Completed enrollment in the SYMPHONY-PE pivotal IDE study evaluating a thrombectomy system for treatment of acute pulmonary embolism across 19 U.S. centers.
Received FDA 510(k) clearance for a comprehensive stroke system that includes large-bore .088" catheters indicated for access and aspiration when used with the system catheters; clearance supported by the Imperative Trial.
FDA 510(k) clearance expanded a continuous-vacuum large-bore thrombectomy system to include pulmonary embolism treatment following pivotal trial results.
Initiated and reported initial successful treatments in a first-in-human study of an investigational low-profile stent designed to enable single antiplatelet therapy after aneurysm treatment.
Raised institutional financing rounds (including an $85M Series C and subsequent financing rounds) to support commercialization, product development and clinical evidence generation.
Announced an oversubscribed $100 million convertible note financing to support commercialization and investment in next-generation product development, including a robotic platform.
Completed enrollment in the SYMPHONY-PE pivotal IDE study evaluating a thrombectomy system for treatment of acute pulmonary embolism across 19 U.S. centers.
Received FDA 510(k) clearance for a comprehensive stroke system that includes large-bore .088" catheters indicated for access and aspiration when used with the system catheters; clearance supported by the Imperative Trial.
FDA 510(k) clearance expanded a continuous-vacuum large-bore thrombectomy system to include pulmonary embolism treatment following pivotal trial results.
Initiated and reported initial successful treatments in a first-in-human study of an investigational low-profile stent designed to enable single antiplatelet therapy after aneurysm treatment.
Raised institutional financing rounds (including an $85M Series C and subsequent financing rounds) to support commercialization, product development and clinical evidence generation.
Announced an oversubscribed $100 million convertible note financing to support commercialization and investment in next-generation product development, including a robotic platform.